Anti-Human HMG1 Recombinant Antibody (DPH1 .1 mAb) (CAT#: TAB-100CT)

Figure 1 shows representative western blots of recombinant BoxA fragment of HMGB1 with the anti-HMGB1 mAb DPH1.1.

500 ng (lane 1) or 100 ng (lane 2) of the recombinant BoxA fragment of HMGB1 (negative control) and 500 ng (lane 3) or 100 ng (lane 4) of recombinant HMGB1 incubated with either the anti-HMGB1 mAb DPH1.1 (top panel) or a control anti-Box-A subunit Ab control (bottom panel).

Figure 2 Immunofluorescence of anti-HMGB1 mAb DPH1.1

shows representative micrographs of mouse embryonic fibroblasts (MEFs) derived from either wild type (wt) mice or Hmgbl-/- mice that were stained by immunofluorescence with the anti-HMGB1 mAb DPH1.1.

Figure 3 shows migration of 3T3 cells towards HMGB1 in the presence of the indicated concentrations of the anti-HMGB1 mAb, examined using a modified Boyden chamber assay.

Figure 4 shows the results of the in vivo experiments of inflammatory cell recruitment.

Figure 5 are representative graphs of the results of the in vivo experiments.

In particular, sALT levels in the blood (Figure A) and absolute number of Gr-1ʰ ⁱᵍʰ CD11 b⁺ neutrophils (PMNs) recovered from the livers (Figure B) of 6 HBV transgenic mice that received NaCI (white squares), Clo-L and irrelevant (Irr) lgG1 mAb (black triangles) or Clo-L and the anti-HMGB1 mAb DPH1.1 (black circles) along with the intravenous injection of 10⁷ HBV-specific CTLs.